Cellectis(CLLS) - 2022 Q1 - Quarterly Report
Cellectis(CLLS)2022-05-04 16:00EXHIBIT 99.1 Calyxt, Inc., Cellectis' Majority-Owned Subsidiary, Reports Its First Quarter 2022 Financial Results NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- Cellectis S.A. (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop lifesaving cell and gene therapies, announced today that Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company and a majority-owned subsidiary of Cellectis, released today financial results f ...